Brief: Egetis Gets Notice Of Allowance For Patent In The U.S.
09/03/2026 06:03
March 9 (Reuters) - Egetis Therapeutics AB (publ) EGTX.ST: RECEIVES NOTICE OF ALLOWANCE FOR MCT8 DEFICIENCY COMPOSITION PATENT IN THE U.S. ANTICIPATES REGULATORY DECISION ON NDA APPLICATION IN SEPTEMBER 2026 EXPECTS RESULTING PATENT WILL BE ORANGE BOOK-LISTABLE, WITH AN ANTICIPATED EXPIRATION DATE OF 2045 Source text: ID:nMFN868SF5 Further company coverage: EGTX.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))